Precisely Empowers Customers to Unlock Business Value from ESG Reporting with Trusted Data
25.4.2023 16:00:00 EEST | Business Wire | Press release
Precisely, the global leader in data integrity, today announced that it is partnering with customers worldwide to build trust in data for effective ESG reporting processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230425005089/en/
(Photo: Business Wire)
The powerful combination of the Precisely Data Integrity Suite and expert strategic services allows customers to easily combine multiple sources of ESG data for real-time insights, improve confidence in the data quality of ESG metrics, ensure data governance while maintaining compliance with industry regulations, and enrich data with additional datasets to help reveal hidden context. Organizations leveraging data integrity in ESG reporting processes see tangible results such as:
- Improved combination and alignment of fundamental ESG data with datasets that add context and meaning, such as geographic, demographic, or economic data
- Enhanced capture and organization of ESG data from multiple sources, breaking down siloes and making it available in real-time
- More robust standards and controls that ensure ESG data is accurate, consistent, and fit for purpose across operational and analytical systems
- Better governance of data storage, access, use, and exchange between systems while maintaining privacy, security, and compliance with complex regulations
Organizations are increasingly recognizing a need to overhaul ESG reporting, with 41% of finance leaders recently admitting that their current processes would not stand up to the scrutiny of basic assurance standards. With new research from IDC showing that data management concerns are the leading driver for ESG investment, there is no better time for businesses to leverage trusted data to drive accurate reporting processes, achieve meaningful outcomes, and unlock true business value from ESG-focused initiatives.
Vontobel, a globally active investment firm with Swiss roots, have ensured they are ahead of the curve by partnering with Precisely to focus on data integrity. The firm not only ensures that all investment strategies are ESG compliant, but goes one step further by setting its own additional sustainable investment criteria to ensure the best possible investment solutions for clients. The optimization of the ESG data processes for the portfolio valuation is crucial - this includes comprehensive data analysis as well as quality and completeness checks.
"Collecting data is nothing new for investment companies, but the challenge now is how to cater to the new volumes of data needed for meaningful ESG measurement and figure out which data elements are the most important,” said Christina Schack, Head of Data Platform at Vontobel. “Using proper tools to automate data quality checks in the data cleansing process is very important to handle and control the immense amount of ESG data. Implementing automated checks and ingestion of the data has greatly helped to reduce the manual work and achieve more accurate analysis for investment strategies."
Verisk Maplecroft, a leading global risk consultancy firm and specialist in sustainability, resilience, and ESG, also recognizes the importance of ESG reporting powered by accurate, consistent, and contextual data, particularly when combined with the right expertise:
“A more powerful way to approach ESG reporting is to hold it to the same standard of governance, processes, controls, assurance, and expertise that you would with your financial reporting,” said Mikkel Skougaard, Director of ESG Reporting and Strategy at Verisk Maplecroft. “Developing a data-driven ESG report is the most important factor, but this needs to be supported with high-quality contextual narrative in order to unlock maximum value.”
Skougaard will be in attendance at Precisely’s upcoming Data Integrity Summit, Trust ’23, joining Precisely CRO Pat McCarthy and Matthew Rusk, Head of Global Reporting Initiative (GRI) North America for a panel discussion on the importance of trusted data in harnessing true business value from ESG reporting, as well as advice for navigating evolving regulations and consumer expectations. The session takes place on May 17 with registration now open.
“Modern business practices demand complete transparency,” said McCarthy. “Investors, employees, and consumers alike want to know the companies they’re investing in, working for, and buying from not only meet their personal standards of ethics but are doing their part to create a better world. To stay compliant and achieve meaningful outcomes businesses need to prioritize data integrity in sustainability reporting and build trust in the data fueling their decisions.”
Learn more about the exciting speaker line up at Trust ’23 and register for your free place today.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005089/en/
Contact information
Press Contact
Emma Forrest (Global)
press@precisely.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
